Presentation is loading. Please wait.

Presentation is loading. Please wait.

MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification.

Similar presentations


Presentation on theme: "MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification."— Presentation transcript:

1 MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. FISH analysis showing amplification of the MET gene in formalin-fixed paraffin embedded (FFPE) tissue sections from 3 patients with colorectal cancer (#1, #2, and #3; A–C) who developed resistance to therapy with the anti-EGFR monoclonal antibodies panitumumab (Pmab) or cetuximab (Cmab). MET (7q31)–specific probe is labeled with Texas red, whereas chromosome 7 centromeric probe D7Z1 (7p11.1–q11.1) is marked in green. IHC staining for MET is shown in the left of each panel. FISH, original magnification ×60; IHC, original magnification ×40. Alberto Bardelli et al. Cancer Discovery 2013;3: ©2013 by American Association for Cancer Research


Download ppt "MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification."

Similar presentations


Ads by Google